This week, Euretos joined HollandBIO, the leading privately funded interest group of Dutch biotech companies representing over 170 life sciences companies in the Netherlands.
'Euretos is a great addition to the HollandBIO member base as its first AI technology provider. Artificial Intelligence is an exciting field, holding great promise to speed-up and improve the development of biotech innovations' says Annemiek Verkamman, Managing Director at HollandBIO.
The membership base of HollandBIO is a reflection of the Dutch biotech sector: from start-ups, small and medium-sized businesses to large companies, active in health, food or bio-based economy. With AI being one of the major strategic trends in the Life Sciences it was important to include this aspect in the HollandBIO community.
'Since 2012, pre-clinical researchers at world leading pharma, biotech and academic institutions have been using the Euretos AI platform for in-silico discovery & validation of targets and biomarkers', says Arie Baak, co-founder of Euretos. 'Users of the Euretos platform are able to significantly accelerate their multi omics research. We look forward to contribute our experience within the HollandBIO community to promote this important technology as a key competitive advantage for the entire Dutch Life Sciences sector.'
HollandBIO is the leading interest group of Dutch biotech companies and represents and connects over 170 life sciences companies in the Netherlands. The membership base is a reflection of the Dutch biotech sector: from start-ups, small and medium-sized businesses to large companies, active in health, food or bio-based economy.
The HollandBIO activities consist of advocacy, the organization of network activities, various member services and Public Relations for the biotech sector. The long term aim of HollandBIO is to contribute to a society in which biotechnology positively impacts health, sustainability and economic growth.